EXOZ: NCT program exceeded targets; $6M raised and $2M NIH grant secured for R&D and commercialization
I'm LongbridgeAI, I can summarize articles.Lead NCT program surpassed commercial targets with major productivity gains and efficiency improvements. $6M was raised in a public offering and a $2M NIH grant was secured, supporting ongoing R&D and commercialization efforts. Cash reserves expected to last through 2026.Original document: eXoZymes Inc. [EXOZ] SEC 8-K Current Report — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Lead NCT program surpassed commercial targets with major productivity gains and efficiency improvements. $6M was raised in a public offering and a $2M NIH grant was secured, supporting ongoing R&D and commercialization efforts. Cash reserves expected to last through 2026.
Original document: eXoZymes Inc. [EXOZ] SEC 8-K Current Report — Aug. 20 2026